Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL

THURSDAY, Aug. 1, 2019 -- For patients with previously untreated chronic lymphocytic leukemia (CLL), ibrutinib-rituximab is more efficacious than chemoimmunotherapy, according to a study published in the Aug. 1 issue of the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news